A novel, blood-based test developed using fragmentomic features of cell-free DNA (cfDNA) detects colorectal cancer (CRC) with a 90.4% sensitivity and shows consistent performance across stages and ...
The test involves using a dedicated chip and fluorescence analysis, in which fragments of cell-free DNA in the blood are ...
A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...
Recent studies in this field have indicated microbial cell-free DNA (mcfDNA) testing as a viable assay capable of identifying pathogens from the bloodstream. However, this technique has not been ...
Study: Toward the simultaneous detection of multiple diseases with a highly cost-effective cell-free DNA methylome test. Image Credit: 3dMediSphere / Shutterstock In a recent study published in the ...
Patterns of Response to Immune Checkpoint Inhibitors in Sarcomas With High Tumor Burden and/or Mismatch Repair Deficiency The Shield test is a blood-based assay that uses multimodal analysis of ...
Exploratory analyses of immune reconstitution biomarkers from a Ph1b study of an investigational, oral, live biotherapeutic, SER-155, in adult allo-HCT. The impact of the use of hypomethylating agents ...
Dear Dr. Roach: I am 85 and healthy apart from polycythemia vera, for which I take aspirin. I was interested in the new blood test for cancer. Is it worthwhile? Dear M.N.: When screening patients for ...
Stanford Medicine researchers have developed a blood test capable of detecting cancers, the ways cancer resists treatments and tissue injury caused by non-cancerous conditions. The new test analyzes ...
Speed is a critical differentiator in therapeutic development. For teams developing DNA and RNA therapeutics, non-viral gene therapies, viral vectors, cell-free protein synthesis workflows, or CRISPR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results